Physician profile
Jun Chung
NPI 1205190659
$7,393.01
in general payments reported to CMS, 2019-2025
28 companies · $2,218 in 2025
The $2,218 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $552 · 2021: $1,102 · 2022: $1,224 · 2023: $336 · 2024: $1,829 · 2025: $2,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,383.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,295.12 | 2019-2025 | Tepezza, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $776.24 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $556.73 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $543.07 | 2020-2025 | Creon |
| Bayer Healthcare Pharmaceuticals INC. | $501.70 | 2022-2025 | |
| Novo Nordisk INC | $492.15 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.37 | 2021-2025 | Jardiance |
| Ardelyx, INC. | $379.43 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $345.13 | 2021-2025 | Strensiq |
| Merck Sharp & Dohme LLC | $282.80 | 2021-2025 | Verquvo |
| Phathom Pharmaceuticals, INC. | $257.47 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $196.03 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $179.76 | 2024-2025 | Zenpep |
| Pfizer INC. | $171.50 | 2019-2021 | |
| Amarin Pharma, INC. | $118.86 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $114.52 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $105.49 | 2023-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $96.41 | 2022-2025 | |
| Penumbra, INC. | $95.68 | 2021 | |
| Gilead Sciences, INC. | $82.24 | 2025 | |
| Glaxosmithkline, LLC. | $81.83 | 2025 | Arexvy, Shingrix |
| Eisai INC. | $55.79 | 2024-2025 | |
| Insmed, INC. | $50.18 | 2025 | Brinsupri, Arikayce |
| Shield Therapeutics INC | $41.82 | 2025 | |
| Biogen, INC. | $27.26 | 2025 | Leqembi |
| Exact Sciences Corporation | $20.42 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $19.21 | 2020 | |
| Abiomed | $14.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.